Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 1:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HGF Clear all
Completed Phase 2 Interventional Results available

Tocilizumab (TCZ) in New-onset Type 1 Diabetes

NCT02293837
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus, T1DM, T1D
Interventions
Tocilizumab (TCZ), Placebo, Standard of Care
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 17 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
San Francisco, California • Stanford, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Sep 10, 2026, 1:00 AM EDT
Terminated Phase 2 Interventional Results available

ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)

NCT04831281
View directory record Official record
Conditions
Parkinson Disease Dementia, Dementia With Lewy Bodies
Interventions
ATH-1017, Placebo
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
40 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Boca Raton, Florida • West Palm Beach, Florida • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 10, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis

NCT03770273
View directory record Official record
Conditions
Indolent Systemic Mastocytosis
Interventions
sarilumab, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Sep 10, 2026, 1:00 AM EDT
Terminated Phase 1 Interventional

-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer

NCT01441128
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung, Adenocarcinoma, Carcinoma, Squamous Cell, Carcinoma, Large Cell
Interventions
PF-02341066/PF-00299804
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 10, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP

NCT06362759
View directory record Official record
Conditions
Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency, Kidney Insufficiency, Chronic, C-Reactive Protein, High Sensitivity C-Reactive Protein, Hs-CRP, hsCRP
Interventions
TOUR006 - 50 MG, TOUR006 - 25 MG, TOUR006 - 15 MG, Placebo
Drug · Other
Lead sponsor
Tourmaline Bio, Inc., a Novartis Company
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
38
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 10, 2026, 1:00 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

NCT01242488
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CDP6038, Tocilizumab (Actemra or RoActemra), Placebo sc, Placebo iv
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
74
States / cities
Mesa, Arizona • Paradise Valley, Arizona • Scottsdale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Sep 10, 2026, 1:00 AM EDT
Active, not recruiting No phase listed Observational

Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study

NCT06654895
View directory record Official record
Conditions
Sepsis, Septic Shock
Interventions
Not listed
Lead sponsor
Bluejay Diagnostics, Inc.
Industry
Eligibility
22 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Gainesville, Florida • Boston, Massachusetts • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 10, 2026, 1:00 AM EDT
Completed No phase listed Observational

International Study of Inflammation in COVID-19

NCT04818866
View directory record Official record
Conditions
Covid19, Outcome, Fatal, Respiratory Failure, Acute Kidney Injury, Inflammation
Interventions
SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase
Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
4,463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Sep 10, 2026, 1:00 AM EDT
Not yet recruiting Phase 2 Interventional

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

NCT07783802
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Interventions
Clazakizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
31
States / cities
Huntsville, Alabama • Tucson, Arizona • Glendora, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 10, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease

NCT01024036
View directory record Official record
Conditions
Multicentric Castleman's Disease
Interventions
Siltuximab, Placebo, Best Supportive Care (BSC)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Sep 10, 2026, 1:00 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Neutralizing Interleukin (IL)-6

NCT07493317
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Tocilizumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 10, 2026, 1:00 AM EDT
Terminated Phase 2 Interventional Results available

Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

NCT01296711
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CDP6038 (olokizumab)
Biological
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 10, 2026, 1:00 AM EDT
Completed No phase listed Observational

Biomarkers of Iron Homeostasis and Responses to Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment

NCT02188758
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Adults - CFPE Treatment
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
South Portland, Maine • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 10, 2026, 1:00 AM EDT
Completed No phase listed Observational

Multicenter Symphony IL-6 Monitoring Sepsis ICU Study

NCT06181604
View directory record Official record
Conditions
Sepsis, Septic Shock
Interventions
Not listed
Lead sponsor
Bluejay Diagnostics, Inc.
Industry
Eligibility
22 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
7
States / cities
Boston, Massachusetts • St Louis, Missouri • Brooklyn, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 10, 2026, 1:00 AM EDT
Completed Early Phase 1 Interventional

Immunologic Response to Negative Cognition in Persons With Chronic Pain

NCT00677911
View directory record Official record
Conditions
Chronic Pain
Interventions
In-vivo pain catastrophizing induction
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Sep 10, 2026, 1:00 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Biomarkers in Obstructive Sleep Apnea

NCT02325687
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Lumbar Puncture (Standard-of-Care)
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years to 84 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 10, 2026, 1:00 AM EDT
Completed Not applicable Interventional

A Study to Evaluate the Ability of TNFR:Fc to Decrease the Amount of IL-6 (Interleukin-6) and TNF-alpha (Tumor Necrosis Factor) in HIV-Infected Patients

NCT00001116
View directory record Official record
Conditions
HIV Infections
Interventions
Tumor Necrosis Factor soluble receptor-immunoadhesin complex
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
3
States / cities
Honolulu, Hawaii • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 10, 2026, 1:00 AM EDT
Completed Phase 2 Interventional

Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia

NCT00060892
View directory record Official record
Conditions
Arterial Occlusive Disease, Peripheral Vascular Disease, Ischemia
Interventions
HGF plasmid
Genetic
Lead sponsor
AnGes USA, Inc.
Industry
Eligibility
40 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2008 · Synced Sep 10, 2026, 1:00 AM EDT
Terminated Phase 2 Interventional Results available

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

NCT04515394
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Tepotinib, Cetuximab
Drug · Biological
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Phoenix, Arizona • La Jolla, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 10, 2026, 1:00 AM EDT
Not yet recruiting Phase 1 Interventional

Anti-Interleukin-6 (IL6) in Calciphylaxis

NCT07708038
View directory record Official record
Conditions
Calciphylaxis
Interventions
Tocilizumab
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 10, 2026, 1:00 AM EDT
Withdrawn Not applicable Interventional

Melatonin in Acute Stroke

NCT03843008
View directory record Official record
Conditions
Stroke, Acute, Ischemic Stroke
Interventions
Melatonin
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Sep 10, 2026, 1:00 AM EDT
Completed No phase listed Observational

Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19

NCT04706533
View directory record Official record
Conditions
Covid19, Kidney Diseases, Inflammation, SARS-CoV Infection
Interventions
Biomarkers of inflammation
Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
3,402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Sep 10, 2026, 1:00 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

NCT03999749
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Nivolumab, Tocilizumab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 10, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Results available

Hepatocyte Growth Factor to Improve Functioning in PAD

NCT03363165
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
VM202, Placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
55 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Sep 10, 2026, 1:00 AM EDT